Abstract：【Objective】To explore the evaluation value of serum free triiodothyronine(FT3) and free thyroxine(FT4) in patients with hyperthyroidism complicated with hyperthyroid heart disease. 【Methods】A total of 84 patients with hyperthyroidism treated in Chang'an District Hospital from January 2021 to January 2023 were selected in the study. The incidence of hyperthyroidism patients complicated with hyperthyroidism heart disease was counted, and patients were divided into concurrent group(10 cases) and non-concurrent group(74 cases) according to whether hyperthyroidism heart disease occurred. The clinical data of patients in concurrent group and non-concurrent group were compared. Multivariate logistic regression analysis was used to analyze the risk factors of hyperthyroidism patients complicated with hyperthyroidism heart disease. The efficacy of FT3 and FT4 in the evaluation of hyperthyroidism patients complicated with hyperthyroidism heart disease was analyzed. 【Results】There were 10 cases of hyperthyroid patients complicated with hyperthyroid heart disease, which showed that the incidence of hyperthyroid heart disease was 11.90%. There were no significant differences in gender, age, diabetes mellitus, smoking history, hyperthyroidism drug use, uric acid, triglyceride, hemoglobin, albumin and infection between the concurrent group and the non-concurrent group(P>0.05). FT3 and FT4 in the concurrent group were higher than those in the non-concurrent group(P<0.05). The results of multivariate analysis showed that both FT3 and FT4 were independent risk factors for hyperthyroid patients complicated with hyperthyroid heart disease(OR=3.256, 3.368, P<0.05). The best cutoff points of FT3 and FT4 in predicting hyperthyroidism complicated with hyperthyroidism heart disease were 10.25 pmol/L and 36.52 pmol/L respectively, and the area under the curve(AUC) was 0.785 and 0.756. The specificity of the combination of FT3 and FT4 was 92.69%, which was higher than that of FT3 and FT4 alone(P<0.05). 【Conclusion】The incidence of hyperthyroid patients complicated with hyperthyroid heart disease is high. FT3 and FT4 have certain value in the evaluation of hyperthyroid patients complicated with hyperthyroid heart disease, but the value of their combined detection is even higher, which can be used as an important reference index for clinical evaluation.
李丹, 黄峰. 血清FT3、FT4水平对甲亢患者并发甲亢性心脏病的评估价值[J]. 医学临床研究, 2024, 41(3): 368-370.
LI Dan, HUANG Feng. Evaluation Value of FT3 and FT4 Levels in Patients with Hyperthyroidism Complicated with Hyperthyroid Heart Disease. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 368-370.
[1] 李斌义,葛洪波,王波,等. 超声斑点追踪技术联合心肌肌钙蛋白T与有效甲状腺素比值在甲亢性心脏病中的联合诊断价值[J].中国超声医学杂志,2021,37(9):998-1001.
[2] 孙加凤,张丽,彭兴,等. 血清NT-proBNP、ALCAT1与25(OH)D联合检测在老年甲亢性心脏病患者诊断中的应用价值[J].老年医学与保健,2021,27(3):598-601.
[3] 郑晓红,孙立娟,史红珍,等. 放射性碘联合丹参注射液对甲亢性心脏病患者FT3、TSH、TRAb及心功能指标的影响[J].中国地方病防治杂志,2019,34(4):437-439.
[4] 韩晨鹏,徐清芳,张美华. 糖尿病甲亢性心脏病患者血浆NT-proBNP水平与心脏功能的关系研究[J].首都食品与医药,2019,26(5):88.
[5] 朱清华. NT-proBNP检测在甲亢性心脏病早期诊断中的应用价值[J].中外医疗,2019,37(34):190-192.
[6] 何源,刘青. 甲亢性心脏病患者血浆NT-proBNP水平与左室功能关系的研究[J].大连医科大学学报,2019,39(4):387-389.
[7] 葛均波, 徐永健. 内科学[M].8版. 北京:人民卫生出版社, 2013:5.
[8] LI H,ZENG R L,LIAO Y F,et al. Association of plasma connective tissue growth factor levels with hyperthyroid heart disease[J].Curr Med Sci,2021,41(2):348-355.
[9] HOU R ,JIN X S ,GAO Y H ,et al. Evaluation of the effects of schisandra chinensis on the myocardium of rats with hyperthyroid heart disease by using velocity vector imaging combined with the estimation of p53 expression and calmodulin activity[J].Evid Based Complement Alternat Med,2020,33(1):110-126.
[10] SHAN D,BAI Y,CHEN Q H,et al. Hyperthyroid heart disease in pregnancy:retrospective analysis of a case series and review of the literature[J].World J Clin Cases,2019,7(19):2953-2962.
[11] ZHANG X J,CHEN L,SHENG J P,et al. The association of autoantibodies in hyperthyroid heart disease combined with pulmonary hypertension[J].Int J Endocrinol,2020,35(6):527-535.
[12] WANG Q,LI C,DI S,et al. Clinical efficacy and safety of traditional Chinese patent medicine for hyperthyroid heart disease: study protocol for a systematic review and meta-analysis[J].Medicine,2020,35(8):1353-1361.
[13] KIM H, PARK J T, LEE J, et al. The difference between cystatin C-and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease[J].Atherosclerosis,2020,335(10):53-61.
[14] SCHEIDT M J, HOHENWALTER E J, PINCHOT J W, et al. FT3 appropriateness criteria® radiologic maement of urinary tract obstruction[J].J Am Coll Radiol,2020,17(5S):S281-S292.
[15] WONG-YOU-CHEONG J J, NIKOLAIDIS P, KHATRI G, et al. FT3 appropriateness criteria® renal failure[J].J Am Coll Radiol,2020,18(5):S174-S188.
2024, Vol. 41 
